
New phone system at TWINCORE
Some extension numbers have changed.

TWINCORE was founded in 2008 by the Helmholtz Centre for Infection Research and the Hannover Medical School. We combine the expertise of medical professionals and scientists from a wide range of disciplines to find answers to the pressing questions in infection research. Our focus: translational research – the bridge between basic science and clinical application.

Some extension numbers have changed.

zukunft.niedersachsen provides €2.7 million in funding for joint project on rare diseases

€100,000 from the German Society for Parkinson's Disease and Movement Disorders
We conduct translational infection research to improve the prevention, diagnosis and treatment of infectious diseases in humans. We focus on three areas that characterize our research work. Find out here how we proceed and what results we achieve.
Under the leadership of our best scientists, various labs are working on different projects within our research topics.
Zhang Y, Matzaraki V, Vadaq N, Blaauw M, Vos W, Groenendijk A, van Eekeren L, Stalenhoef J, Berrevoets M, Rokx C, Delporte M, Otten T, Joosten L, Xu C, Li Y, Vandekerckhove L, van der Ven A, Netea M
Mayer L, Arnold J, Roettele F, Reuter N, Pattekar A, Ohtani T, Ribeiro M, Siwicki R, Bruder K, Obwegs D, Stahl E, Buechel S, Roehlen N, Kolter J, Mansoori Moghadam Z, Alaswad A, Zhumalidova Z, Li G, Liu X, Li Y, Singh A, Villacorta Hidalgo J, Paraskevopoulou M, Yajnik V, Juarez J, Ren Y, Li H, Wherry E, Lewis J, Wu G, Bewtra M, Tomov V, Thimme R, Bengsch B, Hasselblatt P, Picelli S, Hofmann M, Sagar
Ilan S, Bartsch Y, Jung W, Kliuchnikov E, Roy V, Bonifer R, Walker-Sperling V, Borducchi E, Nkolola J, Lauffenburger D, Stieh D, Barouch D, Julg B
Immunomodulatory drugs can have systemic side effects. This project is testing nanocarriers that deliver drugs specifically into myeloid immune cells in order to reduce side effects and increase the local effect.
The project investigates immune reactions in viral hepatitis, in particular the role of hepatocytes and myeloid cells. The aim is to understand immune processes in the liver and to develop diagnostic approaches for the clinic.
The project is developing iPSC-based therapies for MSMD patients, a genetic disease with mutations in the IFN-γ signaling pathway that lead to severe mycobacterial infections. The aim is to improve the treatment prognosis.
Studies in the cell culture model show that only a few disinfectants are effective against HEV, which provides important information on hygiene measures for HEV infections. We are also working together to test vaccines for pigs as HEV reservoirs.

